Interview: Samuel Seidu
The main findings of the paper revealed that Black patients were underrepresented in clinical trials, particularly with respect to the newer diabetes therapies, sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists.